<DOC>
	<DOCNO>NCT02622607</DOCNO>
	<brief_summary>Bone metastasis common patient advanced non-small-cell lung cancer ( NSCLC ) devastate consequence . Preventing delay bone metastasis may improve outcome . Bisphosphonates inhibitor osteoclast-mediated bone resorption . The current indication bisphosphonates include treatment metabolic disorder bone metabolism ( e.g. , osteoporosis Paget 's disease ) , treatment hypercalcaemia malignancy ( HCM ) , prevention skeletal-related event ( SREs）from malignant bone disease . Clinical trial also confirm bisphosphonates , zoledronic acid（ZOL ) particular , prevent bone loss cancer treatment.There also emerge evidence benefit bisphosphonate therapy oncology set extensive . This study evaluate whether addition ZOL 4 mg every 3 month 1 year patient stage IIIB/IV NSCLC could reduce rate bone metastasis , improve progression-free survival ( PFS ) overall survival ( OS ) , delay time bone metastasis .</brief_summary>
	<brief_title>Preventive Effects Zoledronic Acid Bone Metastasis Patients With Stage IIIB IV NSCLC</brief_title>
	<detailed_description>Bone metastasis common patient advanced non-small-cell lung cancer ( NSCLC ) devastate consequence . lead pain , decrease mobility skeletal complication .Preventing delay bone metastasis may improve outcome . Bisphosphonates inhibitor osteoclast-mediated bone resorption . The current indication bisphosphonates include treatment metabolic disorder bone metabolism ( e.g. , osteoporosis Paget 's disease ) , treatment hypercalcaemia malignancy ( HCM ) , prevention SREs malignant bone disease . Clinical trial also confirm bisphosphonates , zoledronic acid particular , prevent bone loss cancer treatment.There also emerge evidence benefit bisphosphonate therapy oncology set extensive . This study evaluate whether addition ZOL 4 mg every 3 month 1 year patient stage IIIB/IV NSCLC could reduce rate bone metastasis , improve progression-free survival ( PFS ) overall survival ( OS ) , delay time bone metastasis .</detailed_description>
	<mesh_term>Zoledronic acid</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>1 . Age 18 70 year age , male female 2. histologically cytologically confirm stage IIIB IV NSCLC diagnosis 3. evidence bone metastatic lesion radiographically confirm bone scintigraphy 4. life expectancy ≥6 month 5. adequate renal , hematologic , hepatic 6 . Eastern Cooperative Oncology Group ( ECOG ) performance status≤2 7 . All patient provide write informed consent 1 . Treatment bisphosphonates 2 . Presence brain metastases 3 . Be allergic ZOL 4. attend unlisted drug clinical trial , currently .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>ZOL</keyword>
	<keyword>Prevention</keyword>
	<keyword>NSCLC</keyword>
</DOC>